未登录 分享 收藏
Taiwan expert consensus on the clinical integration of antibody-drug conjugates in advanced breast cancer 台湾专家共识：抗体偶联药物在晚期乳腺癌中的临床整合 Kao, Li-Chun; Hsu, Chih-Yi; Wang, Ming-Yang; Yang, Ming-Han; Hung, Chin-Sheng; Liao, Guo-Shiou; Lee, Kuo-Ting; Kuo, Wen-Ling; Peng, Meng-Ting; Chung, Wei-Pang; Huang, Chih-Hao; Chen, Shou-Tung; Huang, Chi-Cheng; Lu, Yen-Shen; Liu, Chun-Yu 分享 收藏
分享 收藏
分享 收藏
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort Capivasertib 联合 Fulvestrant 治疗HR阳性/HER2阴性晚期乳腺癌：CAPItello-291研究扩展的中国队列 Hu, Xichun; Zhang, Qingyuan; Sun, Tao; Xiong, Huihua; Li, Wei; Teng, Yuee; Lu, Yen-Shen; Tseng, Ling-Ming; Yan, Min; Li, Hongsheng; Pang, Danmei; -Chen, Shin-Cheh; Chen, Wenyan; Jiang, Ou; Wang, Jingfen; Wu, Xinhong; Wang, Xian; Zang, Aimin; Wang, Xiaojia; Collins, Julie M.; Fan, Ethan; Jiang, Lin; Zeng, Xiaoling; Turner, Nicholas C. 分享 收藏
分享 收藏
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2,-3, and-7 trials MONALEESA-2、-3和-7试验中，使用基线和治疗结束时的循环肿瘤DNA样本，评估接受ribociclib联合内分泌治疗或仅接受内分泌治疗患者的获得性基因改变。 Andre, F.; Solovieff, N.; Su, F.; Bardia, A.; Neven, P.; Yap, Y. S.; Tripathy, D.; Lu, Y. -S.; Slamon, D.; Chia, S.; Joshi, M.; Chakravartty, A.; Lteif, A.; Taran, T.; Arteaga, C. L. 分享 收藏
A retrospective study to investigate the prevalence and describe the treatment outcomes of HER2-low unresectable and/or metastatic breast cancer in Taiwan: The RetroBCHER2L-TW study 一项回顾性研究，旨在调查台湾地区HER2-low不可切除和/或转移性乳腺癌的患病率并描述其治疗结局：RetroBCHER2L-TW研究 Tseng, L-M.; Huang, P-H.; Lee, K-T.; Hsu, C-Y.; Lee, Y-H.; Chen, H-W.; Lu, Y-S.; Huang, C-C.; Tsai, Y-F.; Chao, T-C.; Lai, J-I.; Liu, C-Y.; Yang, W. C.; Huang, Y-T.; Huang, C-Y.; Lin, Y-C. 分享 收藏
Analysis of Asian and non-Asian patients (pts) from the NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in pts with HR+/HER2L early breast cancer (EBC) 亚洲和非亚洲患者(pts)在NATALEE试验中，接受ribociclib(RIB)联合非甾体类芳香化酶抑制剂(NSAI)治疗人表皮生长因子受体2低表达激素受体阳性早期乳腺癌(EBC)的分析 Xu, B.; Stroyakovskiy, D.; Sohn, J.; Park, Y. H.; Huang, C-S.; Lu, Y-S.; Jung, K. H.; Chan, A.; Zhang, J.; Lee, J.; Kim, J. H.; Chung, C-F.; Slamon, D.; Sakalosh, V.; Gao, M.; Amin, K.; Islam, S.; Im, S-A. 分享 收藏
分享 收藏
Survival outcomes of young-age female patients with early breast cancer: an international multicenter cohort study Kim, J.; Kim, J.; Seo, K. H.; Lee, K. -H.; Park, Y. H.; Lin, C. -H.; Lu, Y. -S.; Ueno, T.; Yap, Y. -S.; Wong, F. -Y.; Tan, V. K. M.; Lim, G. -H.; Tan, S. -M.; Yeo, W.; Liu, Q.; Leung, R.; Naito, Y.; Li, H.; Lee, H. -B.; Han, W.; Im, S. -A. 分享 收藏
Dato-DXd vs. chemotherapy for patients with inoperable/ metastatic HR+/HER2L breast cancer: TROPION-Breast01 Asian subset Tsurutani, J.; Hattori, M.; Im, S.; Wang, S.; Lu, Y.; Sohn, J.; Zhang, Q.; Park, Y.; Lee, K.; Ozaki, Y.; Jiang, Z.; Chung, W.; De Laurentiis, M.; Pernas, S.; Xu, L.; Khan, S.; Denduluri, N.; Pistilli, B.; Bardia, A.; Xu, B. 分享 收藏
Characteristics and transcriptional regulators of spontaneous epithelial-mesenchymal transition in genetically unperturbed patient-derived non-spindled breast carcinoma Lien, Huang-Chun; Yu, Hui-Chieh; Yu, Wen-Hsuan; Lin, Su-Fang; Chen, Tom Wei-Wu; Chen, I-Chun; Hsiao, Li-Ping; Yeh, Ling-Chun; Li, Yu-Chia; Lo, Chiao; Lu, Yen-Shen 分享 收藏
Efficacy and safety of ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2-early breast cancer (EBC) in NATALEE 瑞博西利（RIB）联合非甾体类芳香化酶抑制剂（NSAI）在年轻激素受体阳性/人表皮生长因子受体2阴性早期乳腺癌（EBC）患者（pts）中的疗效与安全性研究（NATALEE研究）。 Loi, S.; Stringer-reasor, E.; Frenel, J-S.; Reinisch, M.; ORegan, R.; De Laurentiis, M.; Park, Y. H.; O'Dea, A.; Lu, Y-S.; Gonzalez, V.; Gao, M.; Waters, S.; Hu, H.; Xu, B. 分享 收藏
Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator's choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2e breast cancer (BC) datopotamab deruxtecan（Dato-DXd）与研究者选择的化疗方案（ICC）在经治、不可手术/转移性HR+/HER2e乳腺癌（BC）患者中的不良事件（AEs）的暴露调整发生率（EAIRs），来自TROPION-Breast01研究。 Rugo, H. S.; Bardia, A.; Im, S-A.; Pernas Simon, S.; De Laurentiis, M.; Wang, S.; Martinez, N.; Santos Borges, G.; Cescon, D.; Hattori, M.; Lu, Y-S.; Tsurutani, J.; Tolaney, S. M.; Mapiye, D.; Atuah, K.; Verma, D.; Khan, S.; Xu, B.; Pistilli, B.; Jhaveri, K. 分享 收藏
SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials Borrego, Manuel Ruiz; Lu, Yen-Shen; Reyes-Cosmelli, Felipe; Park, Yeon Hee; Yamashita, Toshinari; Chiu, Joanne; Airoldi, Mario; Turner, Nicholas; Fein, Luis; Ghaznawi, Farhat; Singh, Jyotika; Pantoja, Kristyn; Schnell, Christian; Akdere, Murat; Chia, Stephen 分享 收藏
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer Noguchi, Emi; Yamanaka, Takashi; Mukai, Hirofumi; Yamamoto, Naohito; Chung, Chi-Feng; Lu, Yen-Shen; Chang, Dwan-Ying; Sohn, Joohyuk; Kim, Gun Min; Lee, Kyung-Hun; Lee, Soo-Chin; Iwasa, Tsutomu; Iwata, Hiroji; Watanabe, Kenichi; Jung, Kyung Hae; Tanabe, Yuko; Kang, Seok Yun; Yasojima, Hiroyuki; Aogi, Kenjiro; Tokunaga, Eriko; Sim, Sung Hoon; Yap, Yoon Sim; Matsumoto, Koji; Tseng, Ling-Ming; Umeyama, Yoshiko; Sudo, Kazuki; Kojima, Yuki; Hata, Tomomi; Kuchiba, Aya; Shibata, Taro; Nakamura, Kenichi; Fujiwara, Yasuhiro; Tamura, Kenji; Yonemori, Kan 分享 收藏
Interaction of base excision repair gene polymorphism and estrogen-DNA adducts in breast cancer risk among East Asian women Chen, Hsing-Wu; Kuo, Wen-Hung; Lu, Yen-Shen; Chen, I. -Chun; Hu, Fu-Chang; Wang, Ming-Yang; Zahid, Muhammad; Rogan, Eleanor G.; Cheng, Ann-Lii; Lin, Ching-Hung 分享 收藏
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study 在先前接受过治疗的HER2-low不可切除/转移性乳腺癌的亚洲患者中，曲妥珠单抗deruxtecan与医生选择的治疗: DESTINY-Breast04研究的亚组分析 Yamashita, Toshinari; Sohn, Joo Hyuk; Tokunaga, Eriko; Niikura, Naoki; Park, Yeon Hee; Lee, Keun Seok; Chae, Yee Soo; Xu, Binghe; Wang, Xiaojia; Im, Seock-Ah; Li, Wei; Lu, Yen-Shen; Aguilar, Cecilia Orbegoso; Nishijima, Soichiro; Nishiyama, Yuji; Sugihara, Masahiro; Modi, Shanu; Tsurutani, Junji 分享 收藏
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment 原位HER2 RNA表达预测接受新辅助化疗和anti-HER2靶向治疗的HER2-positive乳腺癌患者的病理完全缓解 Lien, Huang-Chun; Lo, Chiao; Lee, Yi-Hsuang; Lin, Po-Hang; Wang, Ming-Yang; Kuo, Wen-Hung; Tsai, Li-Wei; Lu, Yen-Shen; Hu, Hsiang-Wei; Li, Yu-Chia; Huang, Chiun-Sheng 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏